StockIQpro
NASDAQ:AMLX

Amylyx Pharmaceuticals, Inc.

Track all markets on TradingView
Track all markets on TradingView

Amylyx Pharmaceuticals, Inc.'s revenue fell 100.0% in fiscal 2025 to $0. Free cash flow was −$123.5M, and the diluted share count rose 38.8%.Summary generated from Amylyx Pharmaceuticals, Inc.'s SEC filings. Latest annual report filed Mar 3, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$0
Revenue growth−100.0%
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−61.6%
Debt / equityn/a
Free cash flow−$123.5M
FCF marginn/a
Share count change+38.8%

Financials

Fiscal years, $M
Item20212022202320242025
Revenue022381870
Operating income−83−20139−315−153
Net income−88−19849−302−145
Free cash flow−75−18211−168−123

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations